Viking Holdings (VIK) Stock News

Viking (VIK) announced delivery of the Viking Rota, a 190-guest river ship. The vessel will sail Rhine, Main and Danube itineraries. Viking also reiterated plans to add 18 river ships by 2028, 11 ocean ships by 2032 and two expedition ships by 2031.

Viking Therapeutics announced the initiation of Part 2 of a maintenance dosing study for VK2735, its dual GLP-1/GIP agonist. The trial will test oral and subcutaneous maintenance regimens after initial weight loss with weekly subcutaneous dosing. Results are expected in 2027.

Viking Therapeutics closed its upsized offerings of 9,035,714 common shares at $35.00 each and $258.75M in 2.00% convertible notes due 2032. Underwriters fully exercised options on both tranches. Net proceeds of ~$547.8M will fund VK2735 and VK3019 programs.

StoneX began coverage of Viking Holdings (VIK) with a Buy rating. No price target or investment thesis was provided.

StoneX initiated Viking with a buy rating and $99 price target. Analyst Mike Hickey says the company's direct marketing and affluent customer base reduce reliance on discounting. Current booked-rate strength should support growth despite industry headwinds. Viking up 1% premarket to $80.32.

Shares of Viking Therapeutics (VKTX) dropped 12% premarket after the company priced an upsized common stock and convertible note offering. The offerings were increased from the original $200 million each to a larger deal, adding dilution and debt. Settlement is set for Friday.

Viking Therapeutics priced an upsized $500M offering of common stock and convertible senior notes. The offering will increase outstanding shares and add convertible debt, diluting existing holders.

Viking Holdings Q2 2026 earnings beat estimates across key metrics.